Advanced therapies like CAR T-cell treatment require coordination across clinicians, regulators, patient advocates, and health system stakeholders.
Our new paper in Frontiers in Hematology explores the challenges and opportunities for equitable CAR T-cell therapy access +
Tailored infectious screening, including endemic pathogens, is critical in CAR-T candidates in endemic areas. Read in Blood Global Hematology: https://t.co/CXAE12d9iK #CARTCell#BloodGlobal
O Dr. Jayr Schmidt Filho (A.C.Camargo Cancer center), um dos palestrantes do V Multirregional SBTMO 2026, convida a todos para participarem do nosso Encontro de Prevenção e Tratamento de Recaídas pós TCTH, que ocorrerá na próxima semana, dia 13 de março! https://t.co/P8EMVWEUd9
Great session at Brazilian Lymphoma Conference (BLC) 2025 from @abhhoficial: traditional debate on CART vs Bispecifics, with @GuiperiniMD, and moderated by Daniel Tabak and Belinda Simoes. The panel's overall opinion is that both therapies are complementary and not antagonistic.
Honored to participate in Lymphoma Experience (LEx), organized by @cytohance@iHematologo and @nico30f in Puerto Varas 🇨🇱
Pleasure to discuss the reality of CAR-T cell treatment in LATAM, sharing our experience through clinical cases presented by @ThaisFischer4 🩸🧬
Dr. @jayrsf_ hematologista, transplante de medula óssea e terapia celular, líder do centro de referência de neoplasia hematológicas do AC Camargo Câncer Center, tem uma mensagem sobre o Dia Mundial do Doador de Medula Óssea!
#globaldonordrive#thankyoudonor#WMDD23#redome30anos
Amanhã, dia 03/08 (quinta-feira), às 14h, teremos a 39ª Reunião dos Gerentes de Dados da SBTMO.
Para participar, acesse no horário de início da atividade o link zoom:
https://t.co/987hqekucM
ID da reunião: 892 0245 2945
Senha de acesso: gdsbtmo
TRANSCEND #CLL 004
Of 137 leukapher 117->lisocel
53 (DL1=4; DL2=49) in primary efficacy ax (PAS)
median 5 lines
All BTKi exp
CR/CRi in PAS 18% ORR 43% uMRD PB 63%
mDOR 35m
PFS 12m
Responders->✅DOR
CRS 85% G3 8.5%
NE 45% G3 18%
Effective in v high risk but notable tox
#ASCO2023